FDA Approves Repatha? (evolocumab) In Pediatric Patients Age 10 And Older With Heterozygous Familial Hypercholesterolemia
THOUSAND OAKS, Calif.,?Sept. 24, 2021?/PRNewswire/ --?Amgen?(NASDAQ:AMGN) today announced that the?U.S. Food and Drug Administration?(FDA) has approved Repatha??(evolocumab) as an adjunct to diet and other low-density lipoprotein cholesterol (LDL-C)-lowering therapies for the treatment of pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH) to reduce LDL-C.
HeFH is an inherited, genetic condition with a prevalence of one in 250 people worldwide.1?High levels of LDL-C starting at birth accelerate the development of atherosclerotic cardiovascular disease, leading to an overall increased risk of cardiovascular events, including heart attack and other vascular conditions, at an earlier age.2?Children with familial hypercholesterolemia (FH) can be normal weight, have a good diet, exercise enough and still have high LDL-C.2,3
"The approval of Repatha for pediatric patients with FH represents a much-needed adjunct treatment option for these children with genetically high cholesterol?who?are unable to manage their high LDL-C with other lipid-lowering agents alone," said?David?M. Reese, M.D., executive vice president of Research and Development at?Amgen. "This milestone further reinforces the safety profile of Repatha and aligns with?Amgen's commitment to addressing the unmet needs of the high-risk cardiovascular community."
The approval is based on the HAUSER-RCT Phase 3b study evaluating the safety and efficacy of Repatha in pediatric patients, 10 - 17 years of age, with HeFH. Monthly treatment with Repatha reduced LDL-C by mean 38% (95% CI: 45%, 31%; p < 0.0001) from baseline compared to placebo, meeting its primary endpoint.4?Reductions in LDL-C were observed by the first post-baseline assessment at the Week 12 time point and were maintained throughout the trial.4?Patients treated with Repatha had improved secondary lipid parameters from baseline in comparison to placebo, including a 35% (CI: 42%, 28%) reduction in non-high-density lipoprotein cholesterol (non-HDL-C) at week 24, a 27% (CI: 32%, 21%) reduction in total cholesterol at week 24 and a 32% (CI: 39%, 26%) reduction in apolipoprotein B (ApoB) at week 24.5?No new safety risks were identified.5?The most common treatment-emergent adverse events (>5% of patients treated with Repatha and occurring more frequently than placebo) included nasopharyngitis, headache, oropharyngeal pain, influenza and upper respiratory tract infection.5
"As pediatric FH is an under-recognized condition that can lead to premature coronary artery disease, it's critically important to have additional treatments that can significantly lower cholesterol," said?Katherine Wilemon, founder and chief executive officer?at?The FH Foundation.
The FDA also approved Repatha as an adjunct to other LDL-C lowering therapies for the treatment of homozygous familial hypercholesterolemia (HoFH) for younger pediatric patients. Repatha was already approved for treatment in HoFH?patients aged 13 and older and is now available as a treatment for patients aged 10 and older.
About Familial Hypercholesterolemia
Elevated low-density lipoprotein cholesterol (LDL-C) is an abnormality of cholesterol and/or fats in the blood.5,6?Familial hypercholesterolemia (FH) is an inherited condition that causes high levels of LDL-C at an early age7. It is estimated that 1 million people in the?U.S.?have FH (heterozygous and homozygous forms), yet less than 10% are diagnosed.8?Heterozygous FH (HeFH) is the more common type of FH and occurs globally in approximately 1 in 250.9?People with HeFH have a 50% chance of passing the condition to their children.8
About HAUSER-RCT Study Design
HAUSER-RCT was a Phase 3b, multicenter, randomized (2:1), double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of 24 weeks of monthly subcutaneous injections of Repatha??(evolocumab) 420 mg (n = 104) versus placebo (n = 53) in patients 10 to 17 years of age with heterozygous familial hypercholesteremia, or HeFH. Randomization was stratified by LDL-C (<4.1 versus =4.1 mmol/L) and age (<14 versus =14 years of age) at screening. Patients were required to be on a low-fat diet and must have been receiving optimized background lipid-lowering therapy (statin at optimal dose, not requiring up titration).The primary endpoint was percent change in LDL-C from baseline to week 24; secondary endpoints included mean percent change in LDL-C from baseline to week 22 and 24, change in LDL-C from baseline to week 24, percent changes from baseline to week 24 in non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (ApoB), total cholesterol/HDL-C ratio, and ApoB/apolipoprotein A1 (ApoA1) ratio. Further safety evaluations included Tanner staging, hormone levels, carotid intimal medial thickness, and computer-based cognitive assessments.
About?Amgen?in the Cardiovascular Therapeutic Area
Building on more than three decades of experience in developing biotechnology medicines for patients with serious illnesses,?Amgen?is dedicated to addressing important scientific questions to advance care and improve the lives of patients with cardiovascular disease, the leading cause of morbidity worldwide.10?Amgen's research into cardiovascular disease, and potential treatment options, is part of a growing competency at?Amgen?that utilizes human genetics to identify and validate certain drug targets. Through its own research and development efforts, as well as partnerships,?Amgen?is building a robust cardiovascular portfolio consisting of several approved and investigational molecules in an effort to address a number of today's important unmet patient needs, such as elevated lipids, including high cholesterol and Lp(a), and heart failure.
About?Amgen
Amgen?is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen?focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980,?Amgen?has grown to be the world's largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
For more information, visit?www.amgen.com?and follow us on?www.twitter.com/amgen.
About Repatha??(evolocumab)
Repatha is a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). Repatha binds to PCSK9 and inhibits circulating PCSK9 from binding to the low-density lipoprotein (LDL) receptor (LDLR), preventing PCSK9-mediated LDLR degradation and permitting LDLR to recycle back to the liver cell surface. By inhibiting the binding of PCSK9 to LDLR, Repatha increases the number of LDLRs available to clear LDL from the blood, thereby lowering LDL-C levels.11
Repatha is approved in 75 countries, including the?U.S.,?Japan,?China?and in all 27 countries that are members of the?European Union. Applications in other countries are pending.
Indications
Repatha??is indicated:
- In adults with established cardiovascular disease to reduce the risk of myocardial infarction, stroke, and coronary revascularization
- As an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C)?lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce LDL?C
- As an adjunct to diet and other LDL-C-lowering therapies in pediatric patients aged 10 years and older with HeFH, to reduce LDL-C
- As an adjunct to other LDL?C-lowering therapies in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH), to reduce LDL?C The safety and effectiveness of Repatha??have not been established in pediatric patients with HeFH or HoFH?who?are younger than 10 years old or in pediatric patients with other types of hyperlipidemia.
- Contraindication:?Repatha??is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha?. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha?.
- Hypersensitivity Reactions:?Hypersensitivity reactions, including angioedema, have been reported in patients treated with Repatha?. If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with Repatha?, treat according to the standard of care, and monitor until signs and symptoms resolve.
- Adverse Reactions in Adults with Primary Hyperlipidemia:?The most common adverse reactions (>5% of patients treated with Repatha??and more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions. From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha?-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. Hypersensitivity reactions occurred in 5.1% and 4.7% of Repatha?-treated and placebo-treated patients, respectively. The most common hypersensitivity reactions were rash (1.0% versus 0.5% for Repatha??and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).
- Adverse Reactions in the Cardiovascular Outcomes Trial:?The most common adverse reactions (>5% of patients treated with Repatha??and more frequently than placebo) were: diabetes mellitus (8.8% Repatha?, 8.2% placebo), nasopharyngitis (7.8% Repatha?, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha?, 4.8% placebo). Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new-onset diabetes mellitus during the trial was 8.1% in patients treated with Repatha??compared with 7.7% in patients that received placebo.
- Adverse Reactions in Pediatric Patients with HeFH:?The most common adverse reactions (>5% of patients treated with Repatha??and more frequently than placebo) were: nasopharyngitis, headache, oropharyngeal pain, influenza, and upper respiratory tract infection.
- Adverse Reactions in Adults and Pediatric Patients with HoFH:?In a 12-week study in 49 patients, the adverse reactions that occurred in at least two patients treated with Repatha??and more frequently than placebo were: upper respiratory tract infection, influenza, gastroenteritis, and nasopharyngitis. In an open-label extension study in 106 patients, including 14 pediatric patients, no new adverse reactions were observed.
- Immunogenicity:?Repatha??is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity with Repatha?.